Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: A retrospective observational study

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Nishida, Yayoi ^a   Takahashi, Yasuo ^a   Nakayama, Tomohiro ^a   Soma, Masayoshi ^a   Asai, Satoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II receptor blocker (ARB); Candesartan; Lipid metabolism; Olmesartan; Renal function; Retrospective observational study

Indexed keywords

CANDESARTAN HEXETIL; CREATININE; HYPERGLYCEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLMESARTAN; POTASSIUM; TRIACYLGLYCEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; CHOLESTEROL; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AGE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LABORATORY TEST; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POTASSIUM BLOOD LEVEL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; AGED; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECT; HYPERLIPIDEMIA; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BLOOD UREA NITROGEN; CHOLESTEROL; CHOLESTEROL, LDL; COHORT STUDIES; CREATININE; DIABETES MELLITUS; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; IMIDAZOLES; KIDNEY; LIPID METABOLISM; MALE; MIDDLE AGED; POTASSIUM; RETROSPECTIVE STUDIES; TETRAZOLES; TRIGLYCERIDES;

EID: 81155158386     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-74     Document Type: Article

References (32)

1. Takai S, Kirimura K, Jin D, Muramatsu M, Yoshikawa K, Mino Y, Miyazaki M. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 2005, 28:593-600. 10.1291/hypres.28.593, 16335888.
2. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, . CHARM Investigators and Committees Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766. 10.1016/S0140-6736(03)14282-1, 13678868, CHARM Investigators and Committees.
3. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, . Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878. 10.1056/NEJMoa011489, 11565519, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.
4. Ritz E, Schmieder RE, Pollock CA. Renal protection in diabetes: lessons from ONTARGET. Cardiovasc Diabetol 2010, 9:60. 10.1186/1475-2840-9-60, 2959007, 20920303.
5. Munger MA. Use of angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P T 2011, 36:22-40. 3046622, 21386934.
6. Marshall TG, Lee RE, Marshall FE. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model 2006, 3:1. 10.1186/1742-4682-3-1, 1360063, 16403216.
7. Kitamura N, Takahashi Y, Yamadate S, Asai S. Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovasc Diabetol 2007, 6:26. 10.1186/1475-2840-6-26, 2098751, 17903269.
8. Devabhaktuni M, Bangalore S. Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. Vasc Health Risk Manag 2009, 5:377-387. 2686256, 19475775.
9. Kyvelou SM, Vyssoulis GP, Karpanou EA, Adamopoulos DN, Zervoudaki AI, Pietri PG, Stefanadis CI. Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol 2006, 47:21-28.
10. Nishida Y, Takahashi Y, Nakayama T, Soma M, Kitamura N, Asai S. Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. Cardiovasc Diabetol 2010, 9:38. 10.1186/1475-2840-9-38, 2933671, 20712859.
11. Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G. ROADMAP Trial Investigators: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011, 364:907-917. 10.1056/NEJMoa1007994, 21388309.
12. Stumpe KO, Agabiti-Rosei E, Zielinski T, Schremmer D, Scholze J, Laeis P, Schwandt P, Ludwig M, . MORE study investigators Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007, 1:97-106. 10.1177/1753944707085982, 19124398, MORE study investigators.
13. Fliser D, Buchholz K, Haller H, . EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004, 110:1103-1107. 10.1161/01.CIR.0000140265.21608.8E, 15313950, EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators.
14. de Vinuesa SG, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, Lahera V, Gomez-Campdera F, Luno J. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: Effects of angiotensin II blockade. J Am Soc Nephrol 2006, 17:S206-S212. 10.1681/ASN.2006080916, 17130263.
15. Fogari R, Derosa G, Zoppi A, Rinaldi A, Preti P, Lazzari P, Mugellini A. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Hypertens Res 2008, 31:43-50. 10.1291/hypres.31.43, 18360017.
16. Takahashi Y, Nishida Y, Nakayama T, Asai S. Adverse effect profile of trichlormethiazide: a retrospective observational study. Cardiovasc Diabetol 2011, 10:45. 10.1186/1475-2840-10-45, 3118327, 21605415.
17. D'Agostino R. Tutorial on biostatistics: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17:2265-2281. 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B, 9802183.
18. Leslie S, Thiebaud P. Using propensity score to adjust for treatment selection bias. SAS Global forum 2007 paper 184-2007., http://www2.sas.com/proceedings/forum2007/184-2007.pdf
19. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55.
20. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000, 11:550-560. 10.1097/00001648-200009000-00011, 10955408.
21. Keidar S, Kaplan M, Hoffman A, Aviram M. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 1995, 115:201-215. 10.1016/0021-9150(94)05514-J, 7661879.
22. Nickenig G, Jung O, Strehlow K, Zolk O, Linz W, Schölkens BA, Böhm M. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am J Physiol 1997, 272:H2701-H2707.
23. Nickenig G, Bäumer AT, Temur Y, Kebben D, Jockenhövel F, Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999, 100:2131-2134.
24. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003, 42:76-81. 10.1161/01.HYP.0000078490.59735.6E, 12796280.
25. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Koh Y, Shin EK. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 2010, 140:73-81. 10.1016/j.ijcard.2008.11.017, 2862263, 19059660.
26. Trenkwalder P, Dahl K, Lehtovirta M, Mulder H. Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. Blood Press 1998, 7:170-175. 10.1080/080370598437385, 9758087.
27. Derosa G, Cicero AF, Ciccarelli L, Fogari R. A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther 2003, 25:1006-1021.
28. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, . RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869. 10.1056/NEJMoa011161, 11565518, RENAAL Study Investigators.
29. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, . Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860. 10.1056/NEJMoa011303, 11565517, Collaborative Study Group.
30. Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA, . CHARM Program Investigators Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol 2007, 50:1959-1966. 10.1016/j.jacc.2007.07.067, 17996561, CHARM Program Investigators.
31. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K, . Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004, 110:2618-2626. 10.1161/01.CIR.0000146819.43235.A9, 15492298, Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees.
32. Bomback AS, Toto R. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination. Am J Hypertens 2009, 22:1032-1040. 10.1038/ajh.2009.138, 19661925.